Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
This study is an open, single arm, dose increasing study to evaluate the safety and efficacy of the combination of mRNA personalized tumor vaccine encoding neoantigen (hereinafter referred to as tumor vaccine) and Sintilimab injection (hereinafter referred to as Sintilimab) in the treatment of advanced malignant solid tumors.
Advanced Malignant Solid Tumors
BIOLOGICAL: Neoantigen mRNA Personalised Cancer vaccine
progression-free survival (PFS), Time Frame: from enrolling to patients disease progressionï¼Œassessed up to 24 months
This study is an open, single arm, dose increasing study to evaluate the safety and efficacy of the combination of mRNA personalized tumor vaccine encoding neoantigen (hereinafter referred to as tumor vaccine) and Sintilimab injection (hereinafter referred to as Sintilimab) in the treatment of advanced malignant solid tumors.